B. Braun Cegat To Present Scientific Findings During An Exhibitor Presentation And Poster Session At The 2015 ARVO Annual Meeting; Will Highlight The Comprehensive Genomic Testing Services And Major Milestone Of 1,000 Patient Samples Tested For Eye Diseas
BETHLEHEM, Pa., April 29, 2015 (GLOBE NEWSWIRE) -- Braun CeGaT, a molecular diagnostics service provider with extensive experience in the area of hereditary eye diseases, will be exhibiting at the 2015 ARVO Annual Meeting held May 3-7 in Denver, Colorado. The Pennsylvania-based company will highlight a catalog of next generation sequencing-based tests that are designed to identify the specific molecular cause of various hereditary forms of eye diseases and will present results of its scientific collaboration with the Eye Clinics of Tuebingen, Germany during an exhibitor presentation on Sunday May 3rd.
The latest update to our diagnostic services for hereditary eye disease includes 21 unique multi-gene panels and covers more than 320 genes known to be associated with retinal and related disorders including, among others, Usher syndrome, retinitis pigmentosa, achromatopsia, and Leber congenital amaurosis. The genes in these panels are sequenced at a very high coverage (800-1000x on average) to increase the probability of finding the causative variant in a patient’s DNA. B. Braun CeGaT has now analyzed over 1,000 patients for eye diseases, giving the company advanced knowledge and expertise in the genetic causes of these diseases. In addition to eye diseases, our growing repository of genetic information also includes data from more than 10,000 patient samples tested in various other disease areas such as epilepsy, oncology, cardiology, neuromuscular disorders, neurodegenerative disorders and metabolic disorders. The complete testing process is performed in-house – from DNA preparation and sequencing to the interpretation of results and issuing of a medical report.
CeGaT’s collaboration partner, Dr. Susanne Kohl from the Centre for Ophthalmology, University of Tuebingen (Germany), will speak during an exhibitor presentation about the scientific discoveries made possibly by using the testing services performed by CeGaT. Additionally, Dr. Nicola Gloeckle, team leader of Panel Diagnostics for Eye Disease at CeGaT, will present a poster detailing the lessons learned from the genetic analysis of more than 900 retinitis pigmentosa patients. Dr. Gloeckle will also be available at our booth for questions.
Exhibitor Presentation
Topic: Extensive Genetic Diagnostic Panels in Clinical Applications
Date/Time: Sunday May 3, 10:30am – 11:00am
Location: Presentation Area in Exhibit Hall, ARVO Annual Meeting (Colorado Convention Center, Denver, CO)
Poster Session
Topic: Unusual genetic findings in 900 patients clinically diagnosed with hereditary retinal dystrophies.
Date/Time: Sunday May 3, 3:15pm – 5:00pm
Location: Poster Board Area in Exhibit Hall (Posterboard # D0221, Abstract # 1244), ARVO Annual Meeting (Colorado Convention Center, Denver, CO)
Visit Booth #1712 during the 2015 ARVO Annual Meeting to learn more about the genetics of eye diseases and B. Braun CeGaT’s diagnostic and research services.
About B. Braun CeGaT, LLC
Braun CeGaT, established in 2014, is the result of a partnership between B. Braun, a leading provider of medical products and services, and the Center for Genomics and Transcriptomics (CeGaT), a Germany-based molecular diagnostic laboratory. The company, which shares its headquarters with B. Braun in Bethlehem, Pennsylvania, was formed to serve the US sequencing and diagnostics market by offering innovative molecular diagnostic services developed by CeGaT to US-based healthcare providers.
CeGaT has created and pioneered diagnostic services for a wide range of disorders including cancer, epilepsy, neuromuscular disease, neurodegenerative disease, eye/vision-related disease, and more. CeGaT’s approach utilizes recent advancements in next generation sequencing technology, allowing for the simultaneous analysis of all genes associated with a particular disease. The information revealed by these tests can be used to identify the underlying cause of the disease in an individual patient and to help guide the course of treatment based on the patient’s unique genetic profile.
Dawn Brooke B. Braun CeGaT, LLC 824 Twelfth Avenue Bethlehem, PA 18018-3524 USA Email: dawn.brooke@bbrauncegat.com
Help employers find you! Check out all the jobs and post your resume.